Pharmaxis Ltd (ASX:PXS)'s Gary Phillips tells Proactive's Andrew Scott they've entered into an option agreement with Aptar Pharma to acquire the worldwide rights to Pharmaxis’ proprietary inhaler Orbital. It's a unique device designed to deliver high payload dry powder to the lungs. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the device and further develop the prototype device to meet unmet market needs.
Pharmaxis grants option deal with Aptar Pharma to acquire its proprietary inhaler Orbital
